Short answer
Pediatrix Medical Group, Inc. (MD) filed an 8-K current report with the SEC on July 15, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Pediatrix issued an update covering recently completed second-quarter fiscal 2026 results.
Pediatrix Medical Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Pediatrix issued an update covering recently completed second-quarter fiscal 2026 results
- Exhibit 99.1 contains the substantive financial results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 payor mix remained stable, with no unfavorable shifts reported by other healthcare companies
- No material changes in net revenue trends versus recent historical periods, reducing near-term reimbursement risk
- FY2026 Adjusted EBITDA guidance reaffirmed at $280 million–$300 million
- Guidance reconciliation implies net income of $152.1 million–$166.7 million
- Q2 results and detailed financial release scheduled for August 4, 2026 before market open
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pediatrix Medical Group, Inc. 8-K filings
Get the next MD 8-K as it lands
Follow MD for push alerts, or ask the research agent what this filing means.